R&D

Dear Research Advocate, Mentioned here last week and the focus of an alliance member webinar earlier this week, the President issued an executive order (EO) extending and imposing new restrictions on worker and student visas. Our statement expresses opposition . Let’s face it — this EO essentially forces our nation to shoot itself in the foot. Bernat Navarro-Serer of the Johns Hopkins Science Policy Group (and a Research!America 2019 student microgrant recipient ) makes the case for sustaining our nation’s long-standing student visa programs . From the article: “ ...a suspension on work visas sends a strong message to current and future students seeking an education in the United States:...
Dear Research Advocate, Our nation’s research enterprise – and thus our society – has long benefitted mightily from the contributions of foreign-born scientists and engineers. In fact, nearly a third of the STEM workforce is foreign-born . A series of immigration-related actions by the executive branch, some already taken and others considered imminent, imperil academic, industry, and independent research across the country with consequences for our economy, our health, and our well-being. We are hosting an alliance member meeting on the state of play and advocacy opportunities next Monday, June 22 at 2 p.m. ET. Alliance members can register here . On Capitol Hill : Recent reports are that...
The May 2020 issue of Research!America's newsletter, The Research Advocate, is now online! In this issue: Research!America's Response to COVID-19 : In January 2020, the first case of COVID-19 was reported in Washington state. The days since then have been unprecedented in global history. The medical and research community, including so many of our alliance members, have taken on the incredible challenge of beating back the novel coronavirus, not just on the front lines in hospitals, but in laboratories across the world working to understand the virus to protect public health. Webinar Explores COVID-19 Vaccines and Treatment : As the COVID-19 pandemic surpasses one million cases in the...
Dear Research Advocate, Yesterday, we hosted a very popular webinar, Understanding the Landscape of COVID-19 Vaccine and Treatment R&D , featuring former FDA Commissioner Mark McClellan, Director of the Duke-Margolis Health Policy Center; Stefano Bertuzzi, CEO of the American Society for Microbiology; and former CDC Director Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health at Merck. All three are working tirelessly to combat COVID-19. In speaking about current public-private research efforts, Dr. Gerberding emphasized: “This is the time we need the most openness, the most transparency, and the...
Dear Research Advocate: Happy Thanksgiving Week! I’m writing early to give us all a holiday. Last Thursday and Friday, l capped off a week of visiting our members at the McKnight Brain Institute (MBI) and the Health Science Center at the University of Florida. Research!America Chair Emeritus, and former member of Congress, the Honorable John Edward Porter, joined me at a Town Hall session during which students, postdocs, faculty, and administrators asked about the best ways to make the case for research with the current and new Congress. At MBI we heard patient advocate extraordinaire Jennifer French, Neurotech Network Executive Director, forcefully articulate the importance of a needed “...
Dear Research Advocate: Last week, the White House laid out its plan for all Cabinet departments to trim their proposed FY20 budgets by 5%. If, as anticipated, these cuts begin with the FY20 spending caps signed into law in 2011 (so-called ‘sequestration’), rather than actual FY19 budgets, the proposed cuts could be shockingly deep—in the 25% range. The potential impact on the NIH budget alone could be a cut of $9.77B, wiping out the increases of the last few years to the point of returning to 2013 funding levels and, when adjusting for inflation, 2001 spending power. Other agencies could take equivalent hits, compromising progress in achieving health goals and sending a clear message to...
Dear Research Advocate: Yesterday, along with 85 partner organizations (more than ever before!), we celebrated Public Health Thank You Day . Hundreds of people took to social media with the hashtag #PHTYD to celebrate and thank the public health heroes who work 24/7 to maximize community health and safety. Overall, PHTYD garnered 10.1 million impressions on Twitter. Leaders in the field, including CDC Director Brenda Fitzgerald, NIH Director Francis Collins, Surgeon General Jerome Adams, APHA Executive Director Georges Benjamin, and World Bank President Jim Kim added their voices to the overwhelming chorus of appreciation. Late last week, news broke of promising discussions in both...
Dear Research Advocate: Yesterday, a high energy discussion on Advocating for Basic Science in a Disease-Focused World at the Society for Neuroscience conference once again revealed the strong appetite for advocacy among scientists, and young scientists in particular. The audience resonated with my point that “you can’t outsource advocacy,” and many were inspired to tweet on the spot. In case you doubt the impact of scientists engaging in advocacy, consider this: Research!America’s Board Chair, former Congressman (R-DE) and Governor Mike Castle, was recently interviewed by the Society for Neuroscience: “Scientists deepened my understanding of the promise of embryonic stem cell research...
U.S. investments in medical and health research and development (R&D) grew by 13.3% over a three year period (2013 – 2015), according to Research!America’s new investment report . However, medical and health R&D represents a small fraction of total spending on health. Currently, the U.S. spends less than 5 cents of every health dollar on R&D to prevent, treat, and cure disease. More than half of Americans (56%) say that is not enough, a recent public opinion survey shows. Industry, including pharmaceutical, medical technolo­gy, biotechnology and health IT companies, invests more in R&D than other sectors. In 2015, industry invested 64.7% of total spending, followed by the...
Dear Research Advocate: While Senate leadership had originally planned to pass a continuing resolution (CR) this week and leave town, negotiations are ongoing. Odds still are that a short-term CR providing $1.1 billion in emergency Zika funding will be signed into law before the 9/30/16 deadline. We’ll keep you posted. The 21st Century Cures Initiative (Cures) is on hold once again. Earlier today, House Energy and Commerce Committee Chairman Fred Upton’s (R-MI-06) staff reported progress on a compromise bill crafted to pass both houses of Congress this year, but said it will not be considered until after the elections. Cures advocacy may have a “rock of Sisyphus” feel to it, but there’s...

Pages

Sidebar Quote

Funding research gives all of us a better chance of living a healthier life.
Pam Hirata, heart disease survivor